Watch JANX. Know when insiders buy.
One email the day a filing lands. Free.
JANX
Janux Therapeutics, Inc.
16.86
+0.61 +3.79%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
73
PASS · shorts 73
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1BP/E —DIV YIELD —FCF YIELD -4.07%REV TTM —NET INCOME −$102.6MNET CASH —52W 12.18 – 34.74SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$31.7M | −$22M | — | -0.35 | $12.5M | $202K | $12.3M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$34.2M | −$24.4M | — | -0.39 | −$12.3M | $273K | −$12.6M | May 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$42.4M | −$31.9M | — | -0.51 | −$28.5M | $106K | −$28.6M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$35.3M | −$24.3M | — | -0.39 | −$12.9M | $93K | −$12.9M | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$45.1M | −$33.9M | — | -0.55 | −$23.8M | $473K | −$24.3M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$34.9M | −$23.5M | — | -0.38 | −$17M | $371K | −$17.4M | May 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$29M | −$20.2M | — | -0.35 | −$16.7M | $42K | −$16.8M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$35.8M | −$28.1M | — | -0.51 | −$2.2M | $25K | −$2.3M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$13.8M | −$6M | — | -0.11 | −$10M | $95K | −$10.1M | Aug 7 |
| Q1 2024 · Mar 31 | — | — | — | −$20.2M | −$14.8M | — | -0.30 | −$14.8M | $197K | −$15M | May 8 |
| Q4 2023 · Dec 31derived | — | — | — | −$16.1M | −$11.8M | — | -0.24 | −$9.9M | $515K | −$10.4M | Feb 26 |
| Q3 2023 · Sep 30 | — | — | — | −$15.8M | −$11.6M | — | -0.25 | −$11.7M | $470K | −$12.2M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$157.7M | −$113.6M | — | -1.83 | −$82.2M | $1M | −$83.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$98.8M | −$69M | — | -1.28 | −$43.8M | $359K | −$44.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$73M | −$58.3M | — | -1.32 | −$50.6M | $1.9M | −$52.4M | — | — |
| FY2022 · to Dec 31 | — | — | −$67.1M | −$63.1M | — | -1.52 | −$42.9M | $6.4M | −$49.4M | — | — |
| FY2021 · to Dec 31 | — | — | −$32.9M | −$32.7M | — | -1.39 | −$17M | $1.5M | −$18.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$4.8M | −$6.8M | — | -7.41 | −$4.4M | $0 | −$4.4M | — | — |
Every number comes from Janux Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.